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Summary 
At present, clinical management of patients infected with M. tuberculosis faces difficult 
problems, such as the worldwide emergence of multidrug-resistant tuberculosis (MDR-TB), 
and the increase in AIDS-associated infections. Development of new drugs with greater or 
distinct antimycobacterial activity than those currently used is, therefore, urgently desired. 
Three main strategies toward this effort are pursued: discovery of new targets, structural 
modification of existing antibiotics, and identification of natural resources for novel antibiotics.  
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1. Introduction 
Infectious diseases remain the largest cause of death in the world today, preceding 
cardiovascular disease and cancer. Tuberculosis (TB) has currently the highest death toll 
from a single infectious agent in the world. It is a major infection in developing countries, as 
well as an increasing problem in developed countries. Data from 2000 indicate that TB, 
caused by infection with Mycobacterium tuberculosis, kills almost 2 million people worldwide 
each year [1]. According to current estimates of the World Health Organisation (WHO), one 
third of the world’s population is infected with the bacillus and about 35 million people will die 
from TB in the first twenty years of the 21st century [2].  
TB mainly affects lung parenchyma (pulmonary TB), but the bacillus can also penetrate other 
organs (extrapulmonary TB), e.g., pleura, lymph nodes, abdomen, genitourinary tract, skin, 
joints and bones, meninges. The most important symptoms are fever, loss of weight, and a 
typical cough, which is accompanied with blood and sputum. 
Recently, improved methods for prevention, detection, diagnosis, and treatment have largely 
reduced the number of people who develop TB and those dying from it. However, during the 
last decade, there has been an unfortunate revival of TB. The resurgence of this disease is 
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caused by the outbreak of MDR-TB [3] and the global HIV pandemic. Indeed, HIV and TB 
form a lethal combination, while each disease speeds up the progress of the other. An 
individual infected with HIV has a 6- to 60-fold greater risk of developing TB [1].  
Standard treatment of TB, as recommended by the WHO, lasts at least 6 months and 
requires a combination of different antibiotics [4]. Usually, the chemotherapy is initiated with 
three drugs: isoniazid, rifampin, and pyrazinamide, often with the inclusion of a fourth drug 
such as ethambutol (or streptomycin). These agents are daily administered in combination 
for two months. In a continuation phase, isoniazid and rifampin are administered biweekly for 
four to twelve months. This standardized treatment regimen avoids failing by acquired 
resistance and is part of the new paradigm in TB treatment: the Directly Observed Treatment 
Short-course (DOTS). This strategy was developed to shorten the length of the illness, to 
lower the risk of death, and to prevent the development of resistant strains. It is built on 5 
elements: political obligation, microscopic provision, drug supply, a monitoring system and a 
direct observation of the treatment.  
Although single-drug therapy can inhibit the majority of organisms in an infected site, it 
permits and, in fact, encourages uncontrolled growth of the resistant mutants. Likewise, 
inadequate treatment, due to poor compliance, inappropriate regimens or irregular drug 
supply, leads to the development of drug resistance.  
In cases of emergency (MDR-TB), the so-called second-line anti-TB drugs are applied. 
However, severe side effects, high costs and the fact that MDR-TB treatment requires 
tailoring to the individual patient and strain impede general use. Examples of second-line 
drugs are ethionamide, fluoroquinolones, p-aminosalicylic acid, cycloserine, kanamycin (a 
synthetic variant of streptomycin), and capreomycin. 
The only vaccine currently in use is the Bacille Calmette-Guérin (BCG) vaccine, which is a 
live attenuated strain of M. bovis. The widespread use of this vaccine has not been able to 
significantly affect the growing pandemic of TB. Although BCG is efficacious in preventing 
the less common yet severe paediatric forms of TB (meningitis and systemic disease) and 
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adult pulmonary TB in some parts of the world, there are clearly populations in high-burden 
countries which do not benefit from the current vaccination regimen. 
An important phase in the development of new anti-tuberculous drugs is the in vitro 
determination of a compound’s capacity to inhibit the growth of M. tuberculosis. For that 
purpose, mycobacteria are cultured in artificial media containing different concentrations of 
the compound under investigation. The determination of the minimal inhibitory concentration 
(MIC) of an antibiotic against mycobacteria by observing their growth in vitro using culture 
media is the cornerstone of antimicrobial selection for treatment of TB. MIC is the lowest 
concentration effecting a reduction in bacterial growth of 99% relative to controls.  
Efforts to develop new drugs for the treatment of TB are hampered by difficulties associated 
with laboratory studies of M. tuberculosis, i.e., mainly the long doubling time of the organism 
(18 to 24 h) and the need to work under stringent level-3 biosafety conditions. The growth of 
M. tuberculosis can be measured by several methods such as monitoring colony formation in 
solid media or turbidity in liquid media. However, the observation of the slow growing M. 
tuberculosis requires long incubation periods. Many investigators tried to circumvent the 
problem by performing tests in liquid media. Several indirect growth observation methods 
have been developed for clinical use. These include observing the production of radioactive 
carbon dioxide in the BACTEC460 system [5] and of oxygen in the Mycobacterium Growth 
Indicator Tube [6] or monitoring the bioluminescence from the Luciferase enzyme that is 
transducted into M. tuberculosis by a specially-engineered virus [7]. In the latter reporter 
gene assay, the ability of a compound to inhibit growth of a mycobacterial reporter strain is 
measured by a decrease in bioluminescence resulting from a reduction in Luciferase 
expression and intracellular ATP levels, both of which are requisites for enzymatic activity. 
Most of these methods can decrease the test period from 3-4 weeks to only 7-10 days. 
Candidate anti-TB drugs must have low toxicity, because patients might need to ingest them 
for a long time. Primary testing for toxicity consists of incubation of the compounds with 
human cells, that are cultivated in vitro and monitored for cytopathic effects. A promising lead 
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compound must have the ability to inhibit the growth of the organism at low concentrations 
and to be toxic to human cells only at high concentrations. These characteristics are 
translated in a high selectivity index (SI). 
The current TB drug arsenal is largely the result of development programs conducted 
between 1940 and 1970 and no new antitubercular drugs except rifabutin and rifapentine 
have entered the clinic since rifampin in the early 1970s. The resurgence of TB, the 
development of MDR-TB, and the discovery that the progression of TB is accelerated in HIV-
positive patients underscore the importance of the development of more efficient drugs to 
combat this disease [8]. Unfortunately, until recently, TB has with few exceptions not been an 
attractive target disease for the pharmaceutical industry, as it was perceived as primarily a 
disease of the poor, and most major pharmaceutical companies did not expect an adequate 
return on investment. Also, clinical development of TB drugs is not straightforward. Efficacy 
trials are tedious and complex and, because few products have been newly registered during 
the last 30 years, current regulatory requirements are not well defined or standardized, and 
previous guidelines are outdated. 
In the Scientific Blueprint for TB Drug Development [9], the objectives are set as follows: 
- to shorten the overall duration of chemotherapy and/or reduce the number of doses, 
- to improve treatment of MDR-TB, and 
- to identify a better treatment for latent TB infections 
It is the purpose of this review to examine the patent literature from 2002 to September 2004 
on the discovery of small-molecule agents that appear useful for the treatment of TB. 
Emphasis will be on new low-molecular-weight compounds. Patents covering formulations, 
drug delivery methods or manufacturing processes are beyond the scope of this review. 
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2. Derivatives of existing drugs 
Using thioacetazone (1) and p-aminosalicylic acid (2) as templates, the University of 
Sciences in Philadelphia prepared some halogenated derivatives [101]. The in vitro 
evaluation of their activity was conducted against M. tuberculosis H37Rv. Compounds were 
also tested for cytotoxicity and for their capacity to inhibit growth of virulent M. tuberculosis in 
an in vivo aerosol mouse model. Thioacetazone is a thiosemicarbazone that is used in 
association with other antimycobacterial agents in the initial and continuation phases of 
antituberculosis treatment. Thioacetazone containing regimens are less effective than the 
recommended short-course regimen and are used in some developing countries to reduce 
drug costs. Its mechanism of action is still unknown. As most active derivative of 
thioacetazone emerged the 3-fluorinated derivative 3. The compound showed a MIC-value < 
0.1 μg/ml and an SI > 312.5. This derivative proved also active against TB strains that are 
resistant to isoniazid, rifampin, ethambutol, kanamycin, and ciprofloxacin. Compared to the 
MIC-value of thioacetazone against M. tuberculosis H37Rv (> 2.0 μg/ml), this fluorinated 
derivative is about 20 times more effective. 
FIGURE 1 
p-Aminosalicylic acid (2) is known to be only active against growing bacilli. Being a mimic of 
p-aminobutyric acid (paba), it inhibits DNA synthesis. 4-Amino-5-fluorosalicylic acid (4) 
emerged as the most active derivative of 2. It displays a MIC-value < 3.13 μg/ml and an SI > 
10. It was also tested for activity against drug resistant strains, where it shows lower but still 
significant activity. Only strains resistant to isoniazid are less susceptible (MIC = 25 μg/ml). 
Compared with the MIC of p-aminosalicylic acid (1.25 μg/ml), this derivative seems less 
active than the original lead. 
Using ethambutol (6), a widely used drug for the treatment of TB, as lead, a large library of 
ethylene diamines with a variety of amine substituents, as well as substituents in the linker 
region has been produced using split-and-pool procedures on a solid support [102, 10]. Initial 
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evaluation of the library was done by a high-throughput screening assay using 
bioluminescent reporter strains that produce light in response to inhibition of the cell wall 
synthesis [11]. A number of hits resulted from this HTS assay. Compound 6, flanked by a 2-
adamantyl and a geranyl substituent, for instance, gave a MIC-value of 0.2 μM against M. 
tuberculosis, compared to 9 μM for ethambutol in the same BACTEC assay [10]. This 
derivative proved also active against 3 MDR patient isolates that were also highly resistant to 
ethambutol and was tolerable in mice up to 600 mg/kg. In vivo assays in mice infected with 
M. tuberculosis H37Rv showed that 10 mg 6 had similar activity as 100 mg ethambutol in 
reducing colony-forming units (CFUs) in spleen, while the same dose had superior activity 
than 100 mg ethambutol in reducing CFUs in lung. 
Rifamycins are potent inhibitors of prokaryotic DNA-dependent RNA Polymerase, with little 
activity against equivalent mammalian enzymes. By inhibiting this enzyme, RNA transcription 
is terminated and cell growth and replication fail. Rifampin (7), a semisynthetic antimicrobial 
drug derived from rifamycin, is a front-line drug in the treatment of TB. Rifampin is crucial in 
achieving sterilization by killing persisting semi-dormant bacilli. Since its introduction in the 
treatment of susceptible TB in the beginning of the 70s, new derivatives have been 
synthesized and evaluated for the treatment of TB (and non TB mycobacteria) [12]. The most 
promising work has been on rifapentine (8), a long-acting rifamycin derivative characterized 
by a lower MIC-value (0.06 μg/ml versus 0.25 μg/ml), which was approved for the treatment 
of TB in the US in 1998.  
WO03084965 describes N-(3-rifamycinyl)carbamates (9) as new substances for treating and 
preventing TB [103]. Compounds were tested ex vivo. The intracellular activity of growth 
inhibition in mouse macrophages, infected with M. tuberculosis H37Rv, was determined by 
counting the CFU/ml. The most active compounds (R = ethyl, methyl) have an 8-fold better 
activity than rifampin. 
FIGURE 2 
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WO04005298 [104] highlights new derivatives of rifabutine Ia (10), a spiropiperidyl-
rifamycine, which has been recommended for HIV-infected TB patients who cannot receive 
rifampin because of interactions with antiretroviral agents. Antimycobacterial activity was 
determined against M. avium 1581. While the known lead 10 displayed a MIC-value of 0.15 
μg/ml, the most active newly synthesised derivatives were slightly less active. Only rifabutin 
IIIa (11) had comparable activity to 10 (MIC-value of 0.2 μg/ml). 
Several patents from Hokuriku Seiyaki are related to novel series of 14-membered macrolide 
derivatives. Among the 1265 erythromycin analogues disclosed in WO00226753 [105], 
several compounds are claimed useful for preventing and/or treating TB. Analogues 13-16 
showed MIC-values in the 0.10-0.20 μg/ml range against different M. avium and M. 
intracellulare strains. Another typical analogue 17 showed a MIC-value of 1.56 μg/ml against 
M. tuberculosis H37Rv and some other M. tuberculosis strains [106], while 12 exhibits the 
same MIC-value against M. avium strains [107]. 
 
3. Drugs on known targets 
A patent by Janssen Pharmaceutica discloses novel 6-bromoquinoline derivatives with 
potent antimycobacterial activity [108]. These so-called diarylquinolines (DARQ) are 
structurally distinct from known broad-spectrum fluoroquinolone antibiotics. With a MIC-value 
of 0.01 μg/ml against M. tuberculosis H37Rv and M. smegmatis strains, one of the four 
possible diastereoisomers of compound 18 showed potent antituberculous activity. 
Unfortunately, the absolute configurations of two stereogenic carbons were not determined. 
A recent paper of Andries at al., however, attributes the activivity to the (1R,2S) diastereomer 
(called R207910) [13]. This paper further reveals that (1R,2S)-5 does not inhibit M. 
tuberculosis DNA gyrase, the target for fluoroquinolones. A gene commonly affected in 
isolated resistant mutants encodes for atpE, a part of the F0 subunit of ATP synthase. This 
indicates that the atpE gene product (i.e., the proton pump of M. tuberculosis ATP synthase) 
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is inhibited by R207910. This distinct target of (1R,2S)-5 implies that there’s no cross-
resistance with existing anti-TB drugs. Pharmacodynamic studies in mice where one of the 
first-line drugs of the triple combination therapy was replaced with 25 mg/kg R207910 proved 
that the activity of each combination containing 207910 was significantly better than the 
standard regimen (e.g. culture-negative lungs after two months).     
Oxazolidinones represent the first completely new class of synthetic antibacterial agents to 
achieve regulatory approval in over 30 years, as exemplified by linezolid (19, Zyvox®). In 
addition to its potent activity against Gram-positive pathogens, this class is of great interest 
because it exerts its antibacterial action by a mechanism distinct from other antibacterial 
agents. Oxazolidinones inhibit bacterial protein synthesis (translation) at a very early step. 
They inhibit the formation of a ribosomal initiation complex involving 30S and 50S ribosomes. 
Because of their unique mechanism, the oxazolidinones are not cross-resistant with any 
known antibiotic. Since this class was found to be endowed with promising antibacterial 
properties many pharmaceutical companies worldwide began research programmes in the 
oxazolinone area, which resulted in an impressive number of patents [14]. However, most 
patents are silent about antimycobacterial activity of the disclosed compounds and only a few 
of the disclosures present compounds that have demonstrated potential as 
antimycobacterials. A general feature of the oxazolidinone derivatives is that only 
enantiomers with a (5S)-acetamidomethyl configuration are known to exhibit antibacterial 
activity. Another feature is that almost all oxazolidinones endowed with antibacterial activity 
carry a phenyl ring attached to the nitrogen atom of the oxazolidinone. 
Linezolid forms an attractive starting point to design anti-TB agents, since it displays a MIC-
value of 0.5 μg/ml against M. tuberculosis and it is known that resistant bacterial mutants to 
linezolid arise at low frequency. Some of the potential side effects associated with extended 
linezolid treatment are toxic optic neuropathy and myelosuppression.  
Ranbaxy disclosed novel oxazolidinone analogues related to eperezolid [109]. All analogues 
have a diazine moiety attached to the phenyloxazolidinone, which is further substituted by a 
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heterocyclic or aromatic ring. Compound 20 with a 5-nitrothien-2-yl moiety directly attached 
to the piperazinyl oxazolidinone core was very effective against the different M. tuberculosis, 
M. intracellulare, M. avium and M. bovis strains tested and MIC-values compared well with 
those of established anti-tuberculosis agents.  
FIGURE 3 
A Lupin Patent disclosed 78 novel oxazolidinones as antibiotic agents against M. 
tuberculosis [110]. Common to all claimed analogues is elongation of the acetamido moiety 
(as it occurs in linezolid). Among the most potent analogues are 21 and its N-oxide (MIC-
value of 0.25 μg /ml for both compared to 0.50 μg /ml for linezolid) and the related 22 (MIC-
value of 0.50 μg /ml). The latter analogue was also potent against resistant clinical isolates 
and showed a favourable acute toxicity profile (LD0 > 1000 mg/kg P.O.). When administered 
at 12.5 or 25 mg/kg to mice infected with M. tuberculosis ATCC27294 5 days/week for 4 
weeks, a mean log10 reduction in colony forming units of 0.20 and 2.3 (in lung) and of 0.26 
and 2.49 (in spleen) was observed. The N-oxide derivatives, which form a novel aspect of 
this invention, are expected to be highly water soluble. 
Previously, the enzyme Glutamine Synthetase (GS) was identified as a potential antibiotic 
target [15,16]. In addition to its key role in nitrogen metabolism in the cell, GS appears to play 
an important role in cell wall biosynthesis, providing substrate for the synthesis of a major 
poly L-glutamate/glutamine cell wall component found exclusively in pathogenic 
mycobacteria. GS is one of the abundantly released proteins by M. tuberculosis. 
Interestingly, only pathogenic mycobacteria release large amounts of GS extracellularly, 
whereas non-pathogenic mycobacteria (e.g., Mycobacterium smegmatis) do not. Exposure of 
M. tuberculosis cultures to L-methionine-SR-sulfoximine (MSO, 23), which irreversibly inhibits 
only the extracellular form of the enzyme as it is unable to cross the cell membrane, causes 
inhibition of bacterial growth (actually, it is L-methionine-S-sulfoxime, one of the four possible 
diastereoisomers, that accounts for the GS-inhibitory activity). The GS inhibitor is believed to 
affect the integrity of the cell wall. It blocks the growth of M. tuberculosis and M. avium within 
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human mononuclear phagocytes, the primary host cells of these pathogens, at 
concentrations that are non-toxic to these mammalian cells. This reflects the fact that purified 
M. tuberculosis GS is one to two orders of magnitude more sensitive to MSO than a 
representative mammalian GS [15]. The efficacy of MSO was measured in vivo in guinea 
pigs. One week after challenge, administration of 1.5 mg/kg.day MSO gave a reduction of the 
CFU with approximately 1 log, compared with control animals. This dose is the maximum 
tolerated dose for guinea pigs infected with M. tuberculosis. 
MSO is not a suitable drug. First, it inhibits γ-Glutamylcysteine Synthetase (γ-GCS), which 
results in glutathione deficiency and mitochondrial damage, thereby causing toxicity of MSO 
in humans. Second, MSO is metabolized in vivo to potentially toxic species, including 
methane sulfinimide and vinylglycoxylate. Third and most importantly, MSO is a known 
epileptogenic agent, due to its inhibition of brain GS in mammals. Hence, analogues that are 
poorly transported into the brain and/or more specific for M. tuberculosis GS would be highly 
desirable. To overcome these drawbacks of MSO, several analogues of MSO were explored 
as described in patent WO04045539 [111]. One of the compounds claimed is α-ethyl-DL-
methionine-SR-sulfoximine (α-Et-MSO, 24), a specific inhibitor of GS. While the inhibitory 
capacity of this compound is comparable to that of MSO, α-Et-MSO is resistant to 
metabolism and, consequently, does not form the toxic products that are formed in vivo from 
MSO. Moreover, it does not enter the brain as readily as MSO and, accordingly, causes 
convulsions in mice only at higher doses. 
The recently obtained high-resolution X-ray crystallographic structure of M. tuberculosis GS 
is that of a relaxed conformation that does not bind substrates or inhibitors [17]. However its 
close similarity with the Salmonella typhimurium GS structure (that has been resolved with 
an inhibitor in the active site) might aid additional efforts towards rational inhibitor design [18]. 
Gallium (a group IIIa transition metal) is known to prevent replication of intracellular 
pathogens. It is thought that gallium (Ga3+) exerts its antibacterial activity through a novel 
mechanism: interference with bacterial iron uptake and metabolism through mimicry of ferric 
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ions (Fe3+). Pathogens such as M. tuberculosis have developed high affinity iron-binding 
molecules, termed siderophores [19], to obtain iron in iron-poor environments. These 
molecules can scavenge iron from intracellular host binding molecules. M. tuberculosis 
produces at least two iron-binding molecules, termed exochelins and mycobactins. 
Replicating bacterial cells have high iron requirement, due to their need to produce 
Ribonucleotide Reductase (RR), a ferric ion-bearing enzyme essential for the synthesis of 
DNA. Gallium is chemically very similar to ferric ions and can be taken up by these cells and 
incorporated into RR instead of iron. As iron-free RR is non-functional, DNA cannot be 
synthesized and the affected cell attempting to replicate will ultimately undergo apoptosis. 
Intravenous infusion of gallium nitrate has significant potential side effects, such as 
nephrotoxicity. WO03053347 presents complexes of gallium with the ionic form of 3-hydroxy-
4-pyrones (from which maltolate (25) is a preferred example) for oral administration that 
represent safer and potentially more effective alternatives to deliver gallium [112]. By a 
transferring-dependent mechanism gallium could then gain entry to macrophages and be 
taken up by mycobacteria. Gallium maltolate (administered per os) proved efficacious in the 
treatment of guinea pigs infected with M. tuberculosis. Necropsies demonstrated that treated 
animals had strikingly less tubercles in lungs and liver relative to untreated animals. The 
decrease of CFUs in spleen was greater than those observed for ethambutol and slightly less 
than for isoniazid. Preparations of orally deliverable pharmaceutical forms of gallium 
maltolate for clinical evaluation in men are disclosed in this patent. 
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4. Agents with unspecified mechanisms of action 
1'-Acetoxychavicol acetate (26) is a natural compound, found in some plants of the family 
Zingiberaceae. The mechanisms of action of the compound are not clear. It could inhibit the 
function of xanthine oxidase and NADPH oxidase. These enzymes are involved in 
superoxide anion production, which is one of the spontaneously occurring toxic substances 
in the body. It also inhibits nitric oxide synthase production. The MIC of 1'-acetoxychavicol 
acetate against M. tuberculosis H37Ra is 0.1 μg/ml (0.1 to 0.5 μg/ml to 30 clinical isolates), 
which is well below the toxic concentration against various mammalian cells [113]. 
FIGURE 4 
Pleuromutilin (27) is a tricyclic diterpenoïd and a naturally occurring antibiotic substance 
produced by the basidiomycetes Pleurotus mutilus and P. passeckerianus. A number of 
further pleuromutilin derivatives have been claimed by Sandoz [114]. The most active 
derivatives, e.g. Valnemulin (28), displayed MIC-values in the range of 0.5 to 8 μg/ml 
depending on the M. tuberculosis strain considered. 
By using the existing lead BM212 [20], researchers at Lupin have discovered novel 
substituted pyrroles endowed with antimycobacterial activity [115]. Compared to the plethora 
of pyrrole derivatives reported earlier and reviewed in this patent, several of the ca. 90 
disclosed derivatives possess higher antimycobacterial activity against clinically sensitive as 
well as resistant strains. The MIC against M. tuberculosis 27294 of 29, the most active 
derivative, is 0.125 μg/ml. When assayed in vivo in Swiss albino mice that were challenged 
with the same strain, 29 compared favourably (on a mg/kg basis) with isoniazid in reducing 
CFUs in lung and spleen, while its LD0 was > 2000 mg/kg, compared to a reported LD50 of 
isoniazid of 139 mg/kg in mice. 
US6268393 contains disclosures on the synthesis and the antimycobacterial activity of 
calanolide analogues [116]. (+)-Calanolide A (30), a known anti-HIV agent which was 
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originally isolated from the rain forest tree Calophyllum lanigerum, was moderately active 
(MIC-value of 3.13 μg/ml against M. tuberculosis H37Rv). 
In WO03042186, Medac revealed dithiocarbamate derivatives endowed with activity against 
different Mycobacterium species. The most active agent is 4-dimethylamino-6-
tetramethylenedithiocarbamoyl-5-nitropyrimidine (31) with a MIC-value of 3.12 μg/ml against 
M. tuberculosis [117]. 
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5. Expert opinion 
With the emergence of resistant forms of M. tuberculosis, it has become essential to develop 
novel antibiotics. Although many new compounds are becoming available for fighting a 
number of infectious diseases, TB has a thin portfolio of new compounds currently in the 
discovery pipeline with near-term clinical potential. This could partly be due to the complexity 
of the research involved and partly due to business considerations. 
The complete genome sequence of the M. tuberculosis laboratory strain H37Rv as revealed 
in 1998 [21], should be a key starting point to identify new viable drug targets and to increase 
our knowledge of virulence genes. Efforts should be made to prioritise potential targets and 
generate further validation evidence (e.g., by gene disruption). Ideally, validated targets 
should be restricted to mycobacterial systems, e.g. enzymes involved in lipid metabolism or 
cell wall biosynthesis. Also, those targets that will contribute most to current TB control 
efforts must be chosen, particularly those that allow shortening the time course of therapy.  
Currently, many bacterial gene products have already been identified, but relatively few are 
properly validated [22]. In some cases, lead inhibitors have been discovered for these target 
enzymes. However, this trend is not commonly translated into new leads with potent in vitro 
activity. A prerequisite to turn a potent enzyme inhibitor into a useful antibiotic is the ability to 
reach its molecular target, generally within the organism, in which the cell wall of the 
mycobacterium presents a major obstacle. One notable exception is Glutamine Synthetase, 
a validated target enzyme, which is exported by pathogenic mycobacteria. Since inhibitors do 
not have to cross the formidable barrier presented by the lipid-rich bacterial cell wall to inhibit 
this target (and probably also other extracellular proteins), this looks promising for developing 
new antibiotics.  
It is striking that the majority of compounds with anti-mycobacterial potential disclosed in 
recent patents are the result of development efforts aimed at finding broad-spectrum 
antibacterial agents or at redesigning and optimising existing anti-tuberculars. Although some 
- 16 - 
scepticism exists against the co-development of broad-spectrum antibacterials for TB [23], 
several members of the oxazolidinone class show promising preliminary results against TB in 
in vitro, animal, and off-label studies. 
An important exception to this trend is R207910, which is proved to inhibit a previously 
unadressed target (proton pump of ATP synthase) and has a unique spectrum of potent and 
selective mycobacterial activity [13].  Extensive studies have demonstrated that it is equally 
effective against MDR TB strains as to antibiotic-susceptible strains [13]. Since this quinoline 
has both early and late bactericidal activity, it is believed to be a promising new TB drug 
candidate.   
Remarkably, no new claims on fluoroquinolone antibiotics for TB infections have been 
reported in the period considered. For over a decade, significant advance in TB treatment 
has arisen from development of fluoroquinolone broad-spectrum antibiotics (e.g., 
ciprofloxacin, ofloxacin, and levofloxacin). These drugs have joined the armamentarium of 
antituberculous agents, i.e. as preferred second-line drugs for MDR-TB.  
Very often, patents rely on in vitro experiments to evaluate the potential of the considered 
compounds as anti-tuberculars. However, it should be noted that an antimicrobial compound 
active against M. tuberculosis in vitro does not necessarily indicate in vivo activity. To be 
gifted with in vivo activity, an antibiotic must penetrate the host cell and reach the organism 
within its unique intracellular compartment, a specialized, membrane-bound phagosome [24]. 
Therefore, it is desirable to assess the in vivo potential of in vitro leads as early as possible in 
a drug evaluation strategy. In such in vivo assays factors as drug absorption, distribution, 
metabolism, and clearance also become pertinent. 
In addition, it is important to distinguish targets that are likely to be essential for in vitro 
survival from those that may be necessary for persistence of the organism (and may not be 
expressed in in vitro culture). While the former may yield drug candidates that might be 
useful tools to overcome MDR-TB, the latter could be useful to identify drugs that might 
shorten the duration of the treatment. Indeed, an underrated issue in the treatment of TB is 
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the killing of the majority of bacilli that reside in cavities (extracellular) [25]. These are 
believed to be composed of an important sub-population of slowly metabolising or dormant 
organisms that are phenotypically resistant (tolerant) to drug action and might cause relapse. 
Nowadays, new leads are not routinely tested for sterilising activity until at a late stage of 
development. In vitro tests based on conditions likely to be found in the extracellular bacilli of 
cavities, have recently been developed [25]. These tests, which are open to automation, are 
able to grade current drugs according to their capacity to sterilize bacilli in the lesions of TB. 
Novel drugs that are able to interfere with bacterial survival under non-replicating conditions 
are highly desirable, since they shorten treatment. Several nitroimidazoles are believed to 
have unique potential to shorten the course of TB therapy by exerting a bactericidal effect on 
non-replicating bacilli [26]. However, no new developments in this area have been claimed 
recently. 
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